It was a day many big biotechs and pharmas feared but one that consumers should celebrate -- the world's first biosimilar monoclonal antibodies were recommended for approval in Europe. The drug set to face a new cheap generic threat is Remicade, a $6 billion rheumatoid arthritis blockbuster and Johnson & Johnson's biggest seller.
In this video, health-care analyst David Williamson discusses the big picture importance of this EU decision, why J&J investors shouldn't panic, and why the company responsible for the biosimilar may deserve a second look.
Follow David on Twitter: @MotleyDavid.
